Elsevier

Brain Research

Volume 698, Issues 1–2, 6 November 1995, Pages 146-154
Brain Research

Differential sensitivity of [3H]7-OH-DPAT-labeled binding sites in rat brain to inactivation by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline

https://doi.org/10.1016/0006-8993(95)00879-UGet rights and content

Abstract

The effects of alkylating agent N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) on the binding of [3H]7-OH-DPAT, a ligand for the D3 dopamine receptor, were assessed in ventral striatal (n. accumbens and olf. tubercle) membranes of adult, male Sprague-Dawley rats. [3H]Spiperone binding to D2-like receptors in striatal membranes was also assayed as a positive control. In vitro, EEDQ was equipotent in inactivating [3H]7-OH-DPAT- and [3H]spiperone-labeled binding sites. In vivo, [3H]spiperone binding was rapidly eliminated in a dose-dependent manner following EEDQ administration. In contrast, [3H]7-OH-DPAT binding was not significantly altered by any dose of the alkylating agent at any time point examined. Depletion of endogenous catecholamines with α-methyltyrosine and reserpine revealed a second, higher affinity binding site for [3H]7-OH-DPAT. Administration of EEDQ in catecholamine-depleted animals reduced [3H]7-OH-DPAT binding by one-third relative to controls and resulted in the detection of a single population of sites. These findings suggest that [3H]7-OH-DPAT labels two distinct populations of binding sites in rat brain membranes, only one of which is susceptible to inactivation by EEDQ. These sites may represent high and low affinity states of the D3 receptor. In addition, this discovery may provide a useful method for examining the function of some D3 receptors in brain independent of other monoaminergic systems.

Referencess (45)

  • BarR. et al.

    Regulation of insulin in normal and abnormal physiology in humans

    Adv. Intern. Med.

    (1979)
  • BelleauB. et al.

    The mechanism of action of irreversible adrenergic blockade by N-carbethoxydihydro-quinolines-model studies with typical serine hydrolases

    Biochem. Pharmacol.

    (1968)
  • BouthenetM.-L. et al.

    Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA

    Brain Res.

    (1991)
  • BradfordM.

    A rapid and sensitive method for the quantification of microgram quantities of protein using the principle of protein dye-binding

    Anal. Biochem.

    (1976)
  • CaineS. et al.

    Modulation of cocaine self-administration in the rat through D-3 dopamine receptors

    Science

    (1993)
  • CarrL. et al.

    Effects of reserpine and α-methyltyrosine on brain catecholamines and the pituitary-adrenal response to stress

    Neuroendocrinology

    (1969)
  • ChioC. et al.

    Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors

    Mol. Pharmacol.

    (1994)
  • CollucciW. et al.

    Regulation of myocardial and vascular α-adrenergic receptor affinity. Effects of guanine nucleotides, cations, estrogen and catecholamine depletion

    Circ. Res.

    (1984)
  • CrockerA. et al.

    Receptor alkylating agents: novel tools for the study of receptor function in the central nervous system of the rat

    Clin. Exp. Pharmacol. Physiol.

    (1989)
  • DjurupR.

    Adrenoreceptors: molecular nature and atopic diseases

    Allergy

    (1981)
  • GopalakrishanM. et al.

    Irreversible modification of the voltage-sensitive calcium channel by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ)

    Biochem. Pharmacol.

    (1990)
  • HessE. et al.

    Differential modification of striatal D1 dopamine receptors and effector moieties by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo and in vitro

    Mol. Pharmacol.

    (1987)
  • Cited by (25)

    • The adverse effects of pramipexole on probability discounting are not reversed by acute D<inf>2</inf> or D<inf>3</inf> receptor antagonism

      2020, European Neuropsychopharmacology
      Citation Excerpt :

      The mechanisms accounting for this up-regulation remain unclear, but they may partially reflect a compensatory response to significant changes in mesolimbic dopamine release. Indeed, we previously documented that the combination of RES and PPX reduced both phasic and tonic release of dopamine (Pes et al., 2017); accordingly, D3 receptor binding is markedly increased by dopamine depletion (Levant, 1995). However, these effects cannot fully account for the observed up-regulation of D3 receptors, given that our previous data showed that RES decreased dopamine release irrespective of its association with PPX (Pes et al., 2017).

    • Dopaminergic denervation switches dopamine D3 receptor signaling and disrupts its Ca<sup>2+</sup> dependent modulation by CaMKII and calmodulin in striatonigral projections of the rat

      2015, Neurobiology of Disease
      Citation Excerpt :

      It remains for future research to elucidate which parameters of receptor–receptor interaction determine how activation of the same pair of receptors, D1 and D3, produces either synergistic or antagonistic effects in the same signaling cascade. Previous biochemical studies have shown enhanced D3R activity after DA depletion in different brain areas, including the striatum (Sato et al., 1994; Levant, 1995; Gurevich et al., 1999; Ishibashi et al., 2002). Our observations show that in addition to this effect, denervation switches signalization pathways in a single structure: the “atypical” mode in which D3Rs potentiates D1R activation at a site upstream of adenylyl cyclase (Avalos-Fuentes et al., 2013) becomes the “typical” inhibitory D2-like response after denervation (Figs. 1 and 2).

    • Positron emission tomography imaging of dopamine D<inf>2</inf> receptors using a highly selective radiolabeled D<inf>2</inf> receptor partial agonist

      2013, NeuroImage
      Citation Excerpt :

      The observation that dopamine depletion did not change the binding potential of [11C]SV-III-130 in the caudate and putamen also suggests that endogenous dopamine has a low in vivo occupancy at D2 receptors. This result agrees well with previous reports that endogenous dopamine protects the D3 receptor (but not the D2 receptors) from alkylation by 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) and the spiperone analog, N-(p-isothiocyanatophenethyl)spiperone (NIPS) (Levant, 1995; Zhang et al., 1999). Occupancy of D3 receptors by endogenous dopamine in vivo is high due to the higher binding affinity of dopamine for dopamine D3 versus D2 receptors (Levant, 1997).

    View all citing articles on Scopus
    View full text